This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The ASCO Weekend Live Blog Recap

CHICAGO ( TheStreet) -- The American Society of Clinical Oncology (ASCO) annual meeting -- the Super Bowl of cancer drug research -- is in full swing. For those that missed all the action captured on my two ASCO live blogs Saturday and Sunday, here's a recap of the news that will be moving biotech and drug stocks Monday:

On Celldex Therapeutics (CLDX):

I just met with Celldex. Data from the Act III study of CDX-110 is consistent with previous studies in Gioblastoma (brain tumors.) The big question -- what's next for CDX-110? A randomized controlled pivotal study needs to be designed and run. Celldex and Pfizer (Celldex's CDX-110 partner) are working on making that happen but Celldex could not give me any firm timeline. The ultimate decision seems to rest with Pfizer.

Celldex does have an interesting and overlooked pipeline. Two cancer drugs entering phase 2 studies this year -- and the studies are going to be randomized and controlled! Hallelujah!!!

I want to dig more into the pipeline but what I saw briefly looks interesting. Celldex is more than CDX-110, which is good. And yes, Celldex CEO Tony Marucci seems like a straight shooter. He'd love to start the CDX-110 phase III study today but he has to work through Pfizer. Investors need to be realistic with timelines.

Celldex is down 30 percent since the ASCO abstracts were released in late May. Is this a buy opportunity? Perhaps with realistic expectations of timelines. I really like the fact that Celldex plans randomized, controlled phase II studies of the pipeline drugs. Data from those studies will not be ready until end of next year, however.

On ImmunoCellular Therapeutics (IMUC.OB) and its ICT-107 "vaccine" for glioblastoma (GBM):

To recap the company's release, treatment with ICT-107 in newly diagnosed GBM, this phase I study showed a 2-year survival of 80%. Median overall survival (OS) not yet reached. Median progression-free survival (PFS) was reported as 17.7 months after surgery.

Interesting data, but it's a single-center study so be wary of patient selection bias. An immune response to the ICT-107 vaccine was only detected in 35 percent of patients, which seems low to me. The investigator at the poster agreed but said that immune response may have been measured at too early a time point.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs